Five new malaria targets that could lead to an effective vaccine
In the largest study of its kind, five new malaria vaccine targets have been discovered by scientists at the Wellcome Trust Sanger Institute and their collaborators. Researchers studied the malaria parasite at its most vulnerable stage – when invading human red blood cells – and identified five targets that lead to a reduction in the parasite’s ability to enter red blood cells.
The results, published today (23 October) in the Proceedings of the National Academy of Sciences (PNAS) show that future malaria vaccines may be most effective if they target multiple parasite factors.
Nearly half of the world’s population is at risk of malaria and more than 200 million people are infected each year. The disease caused the deaths of almost half a million people globally in 2015*.
Despite the large number of deaths, there is no highly effective vaccine currently available for malaria. Over the past 50 years, most attempts to develop vaccines have only focussed on single targets.
In the new study, scientists have discovered five targets for future malaria vaccine development, which they suggest should be targeted in combination. An effective vaccine is urgently needed due to an expanding problem of drug resistance in the parasite.
The team screened 29 potential targets that were all thought to play a role in the parasite’s ability to invade human red blood cells. Red blood cell invasion is an essential step in the parasite’s lifecycle, and is a stage when the parasite is at its most vulnerable and exposed to the immune system.
Researchers raised rabbit antibodies against all 29 targets, then tested the antibodies against two different strains of the deadly Plasmodium falciparum malaria, one from Africa and one from Asia. Of the 29 antibodies, the team discovered five that reduced the parasite’s ability to invade red blood cells in both malaria strains.
“Producing a successful vaccine against parasites is challenging because they are very complex organisms with many components, making it difficult to know which ones to target. By studying the parasite’s genome and working backwards, in a process known as reverse vaccinology, we have discovered five vaccine targets which, if combined, show promise for further development.”
Dr Gavin Wright, one of the study’s authors from the Wellcome Trust Sanger Institute
People naturally exposed to malaria can develop immunity over time. The team worked with collaborators in the US and Mali to see whether the five antibodies they identified were associated with natural protection against malaria in people.
Scientists found that alone, no single antibody gave protection against malaria in people, however combinations of the antibodies did protect against the parasite.
To investigate what was happening at the cellular level, researchers used video microscopy to watch the parasite attempt to invade red blood cells with and without the presence of antibodies. The team discovered that the different antibodies were attacking the parasite at different steps as it invaded the red blood cell. Scientists found that pairing antibodies that each acted at different steps led to a more effective combination.
“Using video microscopy, we were able to see the different antibodies attacking the parasite at various stages as it attempted to invade red blood cells. These results give insight into a new, synergistic view of vaccine development. We believe a new vaccine would be the most effective if it put roadblocks at several points along the parasite’s path into the red blood cells.”
Professor Pietro Cicuta One of the study’s authors, from the University of Cambridge
“This study was only possible due to the scale of studying multiple vaccine targets, and the huge collaborative effort. By bringing together multiple areas of expertise, from genomics to large field studies of patients in Mali, and down to advanced video microscopy observing individual parasites, we have discovered several new vaccine targets that warrant further investigation. It’s a great example of collaborative international science and its potential impact.**”
Dr Julian Rayner Lead author of the study, from the Wellcome Trust Sanger Institute
More information
Funding:
This work was supported by Wellcome (Grant 090851) and the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Sources & Links:
*Malaria statistics: http://www.who.int/features/factfiles/malaria/en/
**To find out more about Together Science Can visit the website: togethersciencecan.org
Publications:
Selected websites
University of Cambridge
The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. To date, 96 affiliates of the University have won the Nobel Prize. Founded in 1209, the University comprises 31 autonomous Colleges, which admit undergraduates and provide small-group tuition, and 150 departments, faculties and institutions. Cambridge is a global university. Its 19,000 student body includes 3,700 international students from 120 countries. Cambridge researchers collaborate with colleagues worldwide, and the University has established larger-scale partnerships in Asia, Africa and America. The University sits at the heart of one of the world’s largest technology clusters. The ‘Cambridge Phenomenon’ has created 1,500 hi-tech companies, 14 of them valued at over US$1 billion and two at over US$10 billion. Cambridge promotes the interface between academia and business, and has a global reputation for innovation.
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease.
Wellcome
Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate.
